DBV Technologies (DBVT) Restructuring Costs (2020 - 2021)
DBV Technologies (DBVT) posted Restructuring Costs of -$920000.0 for Q4 2021, down 136.09% sequentially from $2.5 million in Q4 2020, and down 136.09% YoY from $2.5 million in Q4 2020.
DBV Technologies (DBVT) Restructuring Costs (2020 - 2021) Analysis & Trends
DBV Technologies has reported Restructuring Costs for 2 years, with the latest figure at -$920000.0 in Q4 2021.
- Quarterly Restructuring Costs fell 136.09% year-over-year to -$920000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $1.6 million (changed N/A YoY) and the FY2021 annual result came in at -$920000.0, down 103.91% from the prior year.
- Restructuring Costs declined to -$920000.0 in Q4 2021 per DBVT's latest filing, from $2.5 million in the prior quarter.
- Over five years, Restructuring Costs peaked at $21.3 million in Q2 2020 and troughed at -$920000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | DBV Technologies | 6.08 Bn | 5.90 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -920,000.00 |
| Dec 31, 2020 | 2.55 Mn |
| Sep 30, 2020 | -286,000.00 |
| Jun 30, 2020 | 21.29 Mn |